Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma

Sarcomas are rare tumors with generally poor prognosis, for which current therapies have shown limited efficacy. Histone deacetylase inhibitors (HDACi) are emerging anti-tumor agents; however, little is known about their effect in sarcomas. By using established and patient-derived sarcoma cells with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncogenesis
Autors principals: Di Martile, Marta, Desideri, Marianna, Tupone, Maria Grazia, Buglioni, Simonetta, Antoniani, Barbara, Mastroiorio, Carlotta, Falcioni, Rita, Ferraresi, Virginia, Baldini, Nicola, Biagini, Roberto, Milella, Michele, Trisciuoglio, Daniela, Del Bufalo, Donatella
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833676/
https://ncbi.nlm.nih.gov/pubmed/29472530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0026-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars